Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms

Journal of Neuroinflammation

Ju-Xiong Liu²  Wei Wang¹  Qing-Kang Lv²  Bing-Xu Huang²  Su-Nan Li²  Ya-Long Zeng²  Bing-run Liu²  Hong-Mei Liu²  Wen-Jing Xue²  Jian-Fa Wang¹  Shou-Peng Fu² 

[1] College of Animal Science and Veterinary Medicine, Heilongjiang Bayi Agricultural University, Daqing 163319, P R China;College of Veterinary Medicine Jilin University, Changchun 130062, P R China

关键词: NF-κB;    LPS;    neuroinflammation;    Parkinson’s disease;    GPR109A;    BHBA;   

Others  :  1133206
DOI  :  10.1186/s12974-014-0230-3

 received in 2014-10-11, accepted in 2014-12-21,  发布年份 2015

【 摘 要 】

Background

Accumulating evidence suggests that neuroinflammation plays an important role in the progression of Parkinson’s disease (PD). Excessively activated microglia produce several pro-inflammatory enzymes and pro-inflammatory cytokines, leading to damage to surrounding neurons and eventually inducing neurodegeneration. Therefore, the inhibition of microglial overactivation may be a potential therapeutic strategy to prevent the further progression of PD. β-Hydroxybutyric acid (BHBA) has been shown to suppress lipopolysaccharide (LPS)-induced inflammation in BV-2 cells and to protect dopaminergic neurons in previous studies, but the underlying mechanisms remain unclear. Thus, in this study, we further investigated this mechanism in LPS-induced in vivo and in vitro PD models.

Methods

For the in vitro experiments, primary mesencephalic neuron-glia cultures were pretreated with BHBA and stimulated with LPS. [³H]dopamine (DA) uptake, tyrosine hydroxylase-immunoreactive (TH-ir) neurons and morphological analysis were evaluated and analyzed in primary mesencephalic neuron-glia cultures. In vivo, microglial activation and the injury of dopaminergic neurons were induced by LPS intranigral injection, and the effects of BHBA treatment on microglial activation and the survival ratio and function of dopaminergic neurons were investigated. Four our in vitro mechanistic experiment, primary microglial cells were pretreated with BHBA and stimulated with LPS; the cells were then assessed for the responses of pro-inflammatory enzymes and pro-inflammatory cytokines, and the NF-κB signaling pathway was evaluated and analyzed.

Results

We found that BHBA concentration-dependently attenuated the LPS-induced decrease in [³H]DA uptake and loss of TH-ir neurons in the primary mesencephalic neuron/glia mixed culture. BHBA treatment significantly improved the motor dysfunction of the PD model rats induced by intranigral injection of LPS, and this beneficial effect of BHBA was attributed to the inhibition of microglial overactivation and the protection of dopaminergic neurons in the substantia nigra (SN). Our in vitro mechanistic study revealed that the inhibitory effect of BHBA on microglia was mediated by G-protein-coupled receptor 109A (GPR109A) and involved the NF-κB signaling pathway, causing the inhibition of pro-inflammatory enzyme (iNOS and COX-2) and pro-inflammatory cytokine (TNF-α, IL-1β, and IL-6) production.

Conclusions

In conclusion, the present study supports the effectiveness of BHBA in protecting dopaminergic neurons against inflammatory challenge.

【 授权许可】

   
2015 Fu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al.: Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
• [2]Braak H, Del Tredici K, Rub U, de Vos RAI, Steur ENHJ, Braak E: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003, 24:197-211.
• [3]Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R, et al.: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 2001, 65:135-172.
• [4]Collier TJ, Sortwell CE: Therapeutic potential of nerve growth factors in Parkinson’s disease. Drugs Aging 1999, 14:261-287.
• [5]Jankovic J: Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79:368-376.
• [6]Jenner P: Oxidative stress and Parkinson’s disease. Handb Clin Neurol 2007, 83:507-520.
• [7]Perry VH: Innate inflammation in Parkinson’s disease. Cold Spring Harb Perspect Med 2012, 2:a009373.
• [8]Keane PC, Kurzawa M, Blain PG, Morris CM: Mitochondrial dysfunction in Parkinson’s disease. Parkinsons Dis 2011, 2011:716871.
• [9]Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, et al.: Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson’s disease. Neurobiol Dis 2014, 67:191-202.
• [10]Deleidi M, Gasser T: The role of inflammation in sporadic and familial Parkinson’s disease. Cell Mol Life Sci 2013, 70:4259-4273.
• [11]Hirsch EC, Hunot S, Damier P, Faucheux B: Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 1998, 44:S115-S120.
• [12]Kitamura Y, Itano Y, Kubo T, Nomura Y: Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994, 50:221-224.
• [13]Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A: The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
• [14]Wang MJ, Huang HY, Chen WF, Chang HF, Kuo JS: Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J Neuroinflammation 2010, 7:99. BioMed Central Full Text
• [15]Fu SP, Li SN, Wang JF, Li Y, Xie SS, Xue WJ, et al.: BHBA suppresses LPS-induced inflammation in BV-2 cells by inhibiting NF-κB activation. Mediators Inflamm 2014, 2014:983401.
• [16]Liu YX, Qin LY, Li GR, Zhang W, An LJ, Liu B, et al.: Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 2003, 305:212-218.
• [17]Li FQ, Lu XZ, Liang XB, Zhou HF, Xue B, Liu XY, et al.: Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation. J Neuroimmunol 2004, 148:24-31.
• [18]Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci 2000, 20:6309-6316.
• [19]Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Nitric Oxide 2002, 962:318-331.
• [20]Gayle DA, Ling Z, Tong C, Landers T, Lipton JW, Carvey PM: Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 2002, 133:27-35.
• [21]Zhou HF, Liu XY, Niu DB, Li FQ, He QH, Wang XM: Triptolide protects dopaminergic neurons from inflammation-mediated damage induced by lipopolysaccharide intranigral injection. Neurobiol Dis 2005, 18:441-449.
• [22]Tai W, Ye X, Bao X, Zhao B, Wang X, Zhang D: Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson’s disease models. Neuropharmacology 2013, 75:201-212.
• [23]Izumi Y, Ishii K, Katsuki H, Benz AM, Zorumski CF: beta-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. J Clin Invest 1998, 101:1121-1132.
• [24]Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL: D-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc Natl Acad Sci U S A 2000, 97:5440-5444.
• [25]Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al.: D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003, 112:892-901.
• [26]Lim S, Chesser AS, Grima JC, Rappold PM, Blum D, Przedborski S, et al.: D-beta-hydroxybutyrate is protective in mouse models of Huntington’s disease. PLoS One 2011, 6:e24620.
• [27]Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 6th ed. Elsevier; 2006.
• [28]Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al.: Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000, 295:125-132.
• [29]Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS: Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002, 83:973-983.
• [30]Gebicke-Haerter PJ, Bauer J, Schobert A, Northoff H: Lipopolysaccharide-free conditions in primary astrocyte cultures allow growth and isolation of microglial cells. J Neurosci 1989, 9:183-194.
• [31]Wang K, Yuan CP, Wang W, Yang ZQ, Cui W, Mu LZ, et al.: Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis. World J Gastroenterol 2010, 16:2252-2259.
• [32]Dai JN, Zong Y, Zhong LM, Li YM, Zhang W, Bian LG, et al.: Gastrodin Inhibits Expression of Inducible NO Synthase, Cyclooxygenase-2 and Proinflammatory Cytokines in Cultured LPS-Stimulated Microglia via MAPK Pathways. Plos One 2011, 6:e21891.
• [33]Lawson LJ, Perry VH, Dri P, Gordon S: Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
• [34]Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V: Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A 1991, 88:7438-7442.
• [35]Perry VH, Bell MD, Brown HC, Matyszak MK: Inflammation in the nervous system. Curr Opin Neurobiol 1995, 5:636-641.
• [36]Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G: Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflammation 2006, 3:6. BioMed Central Full Text
• [37]Koprich JB, Reske-Nielsen C, Mithal P, Isacson O: Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 2008, 5:8. BioMed Central Full Text
• [38]Li M, Dai FR, Du XP, Yang QD, Chen Y: Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson’s disease. J Mol Neurosci 2012, 48:225-233.
• [39]Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al.: Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 2009, 23:55-63.
• [40]Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, et al.: The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson’s disease. Eur J Neurosci 2007, 26:417-423.
• [41]Hoban DB, Connaughton E, Connaughton C, Hogan G, Thornton C, Mulcahy P, et al.: Further characterisation of the LPS model of Parkinson’s disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav Immun 2013, 27:91-100.
• [42]Herrera AJ, Castano A, Venero JL, Cano J, Machado A: The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 2000, 7:429-447.
• [43]Hernandez-Romero MC, Arguelles S, Villaran RF, de Pablos RM, Delgado-Cortes MJ, Santiago M, et al.: Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem 2008, 105:445-459.
• [44]Lu X, Bing G, Hagg T: Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 2000, 97:285-291.
• [45]Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al.: Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014, 40:128-139.
• [46]Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, et al.: Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest 2014, 124:2188-2192.
• [47]Offermanns S: The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 2006, 27:384-390.
• [48]Taggart AK, Kero J, Gan X, Cai T-Q, Cheng K, Ippolito M, et al.: (D)-β-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005, 280:26649-26652.
• [49]Zandi-Nejad K, Takakura A, Jurewicz M, Chandraker AK, Offermanns S, Mount D, et al.: The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J 2013, 27:4366-4374.
• [50]Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, et al.: Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 2012, 32:669-676.
• [51]Kulms D, Schwarz T: NF-kappaB and cytokines. Vitam Horm 2006, 74:283-300.